ATYR
aTYR PHARMA INC
NASDAQ · Healthcare · Biotechnology · US
$6.18
−6.79%Oct 29, 2026, 12:00 UTC
aTyr Pharma announced publication in Elsevier of results from its Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis.
Source:Oct 27, 2026, 13:00 UTC
aTyr Pharma announced a 1-for-40 reverse stock split of its issued and outstanding common stock, effective October 28, 2026, at 5:00 p.m. ET.
Source:Oct 19, 2026, 11:00 UTC
aTyr Pharma announced a research collaboration with Albert Einstein College of Medicine, Inc. to further develop and test ATYR2810, a monoclonal antibody targeting the NRP2 receptor.
Source:Oct 13, 2026, 12:00 UTC
aTYR PHARMA INC announced publication of findings demonstrating anti-fibrotic effects of ATYR0101 in the Journal of Biological Chemistry.
Source:Sep 24, 2026, 10:00 UTC
aTyr Pharma announced alignment with the FDA on a global Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease, using FVC as the primary endpoint, with study-related activities expected to begin in the fourth quarter of 2026.
Sep 8, 2026, 15:00 UTC
DelveInsight published a market research report on the sarcoidosis treatment market, forecasting growth through 2036 and highlighting emerging therapies.
Sep 1, 2026, 20:36 UTC
aTyr Pharma provided an update on the expected timing of an FDA response to its protocol submitted in June 2026 for a planned Phase 3 study of efzofitimod in pulmonary sarcoidosis.
Source:Aug 7, 2026, 20:01 UTC
aTyr Pharma announced a corporate restructuring, including a workforce reduction of approximately 60%, to support its efzofitimod program in ILD.
Source: